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ABSTRACT 
Elizabeth A. Andrews: Human Papillomavirus Associated Oropharyngeal Carcinomas In 
Non-Smokers And Non-Drinkers 
(Under the direction of Jennifer Webster-Cyriaque, Valerie Murrah, Daniel Caplan, and 
Carol Shores) 
 
 
Head and neck squamous cell carcinoma (HNSCC) affects 30,000 in the US with 
oropharyngeal carcinoma (OSCC) incidence increasing 3% annually (1973-2001). OSCC’s 
are attributed to tobacco and alcohol, but patients without risk factors develop cancer. High-
risk Human Papillomavirus (HPV) DNA has been consistently detected in 20% of HNSCC’s 
and 50% of the OSCC’s revealing OSCC’s infectious nature. To date case-control studies of 
nonsmoker/nondrinkers (NS/ND) have not been performed. The purpose of this study was to 
determine whether high-risk HPV infection was significantly associated with NS/ND OSCC. 
This case control study consistently detected HPV 14/18 in OSCC (78% cases) of NS/ND 
with oropharynx preponderance (86%).  A sub-study analyzing tumors from intimate partners 
detected identical strains of integrated HPV 16 within each couple.  We have identified close 
links between HPV and OSCC in NS/ND, this justifies early identification of this virus as it 
may act as a crucial marker of malignancy susceptibility.    
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CHAPTER 1 
INTRODUCTION 
 
1.1 BACKGROUND & SIGNIFICANCE 
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity 
and mortality with >500,000 new cases worldwide and 30,000 in the United States each year.  
While the incidence of HNSCC has remained stable, the incidence of oropharyngeal 
squamous cell carcinoma (OSCC), a subset of HNSCC has increased 2% to 3% annually 
among American men from 1973 to 2001(1). The area which is termed the oropharynx 
includes the soft palate, base of tongue, tonsillar region, and posterior pharynx. 
Oropharyngeal carcinoma has a high mortality rate and is characterized by a poor prognosis. 
Based on SEER data from 1995 – 2001, OSCC has an overall 5 year relative survival rate of 
59.4%. This accounts for approximately 8000 deaths per year in the US. In 2005, Shiboski 
found an increase in tongue and tonsil carcinoma in young adults (ages 20-39 yrs), five-fold 
among young men compared with a two-fold increase in older age groups(2). Much is known 
today about the risk factors which can lead to cancer, as well as its poor prognosis, yet oral 
cancer still remains an under diagnosed and often fatal disease.  
Oral Carcinogenesis 
Oral cancer is characterized in general as a disease attributed to multiple exposures, 
with tobacco and alcohol abuse considered to be the major risk factors. Other lifestyle and 
environmental factors have been identified as important contributors in the progression of 
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this disease such as viruses, diet, actinic radiation, and dental factors. Dental factors include 
poor oral hygiene, and defective dental restorations which repeatedly irritate the oral mucosa. 
These factors produce an initial insult to the genetic stability of the affected tissue and trigger 
a cascade of events. Genetic changes have been identified and studied to better identify the 
pathway to carcinogenesis.  
The most frequently mutated gene in human oral cancer is the p53 tumor suppressor 
gene. P53 is a nuclear phosphoprotein which arrests the cell cycle when DNA damage 
occurs.  The Wt p53 acts as a recessive tumor suppressor gene whereas mutants can behave 
as dominant oncogenes. See Figure 1.1 for an example of the mutagenic effect of smoking 
and alcohol. 
FIGURE 1.1 SMOKING & ALCOHOL RELATED TUMORIGENESIS 
Journal of Clinical Oncology, 2005 
When a person smokes or drinks for prolonged periods there is continued mucosal 
damage initially causing an increase in cell number, hyperplasia. Over time, the continued 
exposure to tobacco or alcohol produces a genetic insult and cells begin to divide at a higher 
 
HYPERPLASIA 
DYSPLASIA
&  Alcohol 
3 
 
rate, and in unusual patterns changing the maturation of the epithelium which becomes 
disturbed or dysplastic. Eventually the damaged mucosa cannot recover as p53 is mutated 
allowing unchecked cell division and the affected area progresses to cancer. It has also been 
shown that smokers and alcohol abusers who have had an oral cancer are at a higher risk of 
either a recurrence of the original cancer or having a new cancer in the field which was 
subjected to the offending carcinogen. Approximately 75% of oral cancers can be attributed 
to smoking and/or alcohol abuse (3), but we know that not all smokers get cancer. It is not 
known why some smokers and drinkers are affected by their habit and others are not. 
Interestingly, approximately 25% of cancers occur in people with no known risks suggesting 
cofactors, such as viruses, as a possible etiology (4).  
Viruses associated with Cancer 
The link between viruses and cancer was one of the pivotal discoveries in cancer 
research. Today, it is generally agreed that viruses are involved in 10 - 20% of all cancers (5). 
Many viruses target the p53 and pRb tumor suppressor pathways, altering the cell cycle. 
Hepatitis B infection, for example, is associated with an increased risk of hepatocellular 
carcinoma development. Hepatitis B proteins, such as the Hepatitis Bx protein, regulate 
transcription of many candidate genes for liver carcinogenesis by trans-mechanisms. They 
also alter mechanisms of apoptosis and interfere with nucleotide excision repair of damaged 
DNA (6). This mechanism is similar to the pathogenesis of high-risk types of the human 
papillomavirus (HPV).  HPV has been found to be associated with multiple types of 
epithelial cancers. Another example of viral related carcinogenesis would be Kaposi's 
sarcoma-associated herpes virus (KSHV; also known as kaposi’s sarcoma. Table 1.1 outlines 
viruses associated with cancer. 
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Table 1.1 TUMOR VIRUSES ASSOCIATED WITH CANCER IN HUMANS 
FAMILY VIRUS BENIGN DISEASE TUMOUR 
 
RETROVIRUS 
Human T-
Lymphotrophic Virus 1 
Tropical Spastic 
Paraparesis 
Adult T-cell Leukemia 
/ Lymphoma 
 
PAPILLOMAVIRUS 
Human 
Papillomaviruses 
Benign Warts Cancer of the Cervix, 
Skin, Anus, Oral 
Cavity 
 
HEPADENAVIRUS 
Hepatitis B Virus Hepatitis, cirrhosis Hepatocellular  CA 
 
FLAVIVIRUS 
Hepatitis C Virus Hepatitis, cirrhosis Hepatocellular  CA 
Lymphoma 
 
HERPESVIRUS 
Kaposi’s Sarcoma-
associated herpesvirus 
Castleman’s Disease Kaposi’s Sarcoma 
Lymphoma 
 
HERPESVIRUS 
 
Epstein-Barr Virus Infectious 
Mononucleosis 
Burkitt’s Lymphoma, 
Hodgkin’s Lymphoma, 
Nasopharyngeal CA 
 
Human Papillomavirus  
HPV is a small DNA virus that infects the squamous epithelium of the skin or 
mucosa. It causes both asymptomatic infections and various benign or malignant lesions. Its 
structure consists of a non- enveloped, circular, double stranded DNA of about 8000 base 
pairs. The HPV genome consists of 9 open-reading frame sequences, located on only one of 
the strands of DNA, and is divided into seven early-phase genes (E) and two late-phase genes 
(L). About 10% of the genome is contained in the long control region (LCR) and functions in 
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the regulation of viral gene expression. The remainder of the genome is organized into early 
(E) or late (L) genes, encoded by 50% and 40% of the genome, respectively.  
There are approximately 100 types of HPV. The type is determined by a greater than 
10% sequence difference in the E6, E7, and L1 regions.  The L-late genes encode for proteins 
involved in viral spread, such as capsid proteins. The L1 and L2 genes encode the major and 
minor capsid proteins which are only expressed in terminally differentiated squamous 
epithelial cells. The E-early genes encode nonstructural proteins that regulate virus 
transcription and replication and are expressed in nonproductively infected cells and in 
transformed cells (7). HPV’s have evolved proteins, specifically E6 and E7, to control the 
growth of the epithelial cells they infect. This was a necessity since these viruses require a 
metabolically active, dividing cell in order to complete their life cycle. The viral onco-
proteins E6 and E7 from high-risk HPV types prevent cells from differentiating and 
withdrawing from the cell cycle as they move outward through the cell layers, while those 
from low risk types do not(8).   
The E1 & E2 genes are responsible for initiation of DNA replication. E2 also 
regulates transcription through a feedback mechanism. When there are high levels of E6 and 
E7 the E2 gene will shut down viral transcription. The E2 gene normally binds to a sequence 
in the upstream regulatory region and monitors viral transcription by shutting down E6 & E7. 
In order for malignancy to occur after infection, the virus must become integrated in the host 
genome. When the virus integrates there is a break in the E2 region and the normal repressor 
activity of the virus is rendered ineffective and E6 & E7 are highly expressed. The E5 gene 
from high-risk viruses destabilizes the cell membranes and changes the cellular responses to 
programmed cell death or apoptosis and the E4 gene binds the cytoskeleton proteins and 
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prevents a proper cellular differentiation. E6 binds to the tumor suppressor protein, p53 
marking it for degradation, while E7 binds and inactivates retinoblastoma protein (pRB) (9).  
Figure 1.2 is a diagram of the role of HPV onco-proteins in tumorigenesis.  
 
  
 
 
 
 
 
 
 
FIGURE 1.2 FUNCTION OF HPV ONCOPROTEINS IN TUMORIGENESIS  
 
There are both low-risk and high-risk types of HPV. In benign or low-risk HPV 
lesions, such as those typically associated with HPV types 6 and 11, the HPV genome exists 
as a circular episomal DNA separate from the host cell DNA. These low-risk types are most 
often found in oral squamous papillomas, laryngeal papillomas, and common warts. The 
genomes of high-risk HPV, types 16 and 18, are typically integrated into the host cell DNA 
in malignant lesions. These high risk types are found in most cervical cancers, anal cancers 
and some oral cancers. Integration of the viral genome into the host cell genome is 
considered a hallmark of malignant transformation.  
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Effects of E6 & E7 on Carcinogenesis  
The reason that HPV is a successful tumor virus is due to the expression of the E6 
and E7 onco-proteins, which when expressed at high levels cause the formation of a cancer 
cell and the progression to cancer. The E6 onco-proteins contain zinc-binding motifs and can 
complex with the host cell p53 tumor suppressor protein, thereby inducing p53 degradation. 
When p53 is degraded there is also a decrease in p21, a downstream target in this pathway. 
Because p53 functions in regulating cell growth and tumor suppression, loss of p53 function 
leads to deregulation of the cell cycle and promotes mutation, chromosomal instability, and 
carcinogenesis of the host genome (10). The status of p53 can be analyzed through 
polymerase chain reaction (PCR) and DNA sequencing to determine if it has been mutated in 
a cancer and in most HPV associated cancers the p53 gene is the non-mutated wild-type. This 
wt p53 is targeted for degradation subsequent to high risk E6 binding. 
The E7 onco-protein forms complexes with proteins in the Rb gene family which are 
negative regulators of cell growth. Rb1 regulates cell cycle progression by binding with and 
disrupting the function of transcription factors, such as E2F. Hypophosphorylated forms of 
Rb are thought to block cell cycle progression (9).  HPV E7 binds to hypophosphorylated 
forms of Rb and releases free E2F transcription factors and others, such as p16, into the cell 
leading to transcriptional activation of several genes involved in cell proliferation(11). The 
release of these transcription factors causes a cascade of events in the cell as part of its 
progression through the cell cycle.  When pRB is rendered ineffective by E7, downstream 
upregulation of p16 is seen (12). Because of this effect of E7, p16 can be visualized through 
immuno-histochemistry and is a marker which when found in cancer tissue is a positive 
finding of high risk HPV integration (13). Whether p16 can be utilized as a consistent and 
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reliable method of HPV carcinogenesis is an area of HPV research that needs to be further 
studied. Although, previous studies have shown correlation between p16 overexpression and 
integration status (14). Viral integration into the host DNA is necessary for malignancy to 
occur. Once HPV is integrated, high risk HPV E6 and E7 work in concert to effectively 
transform epithelial cells and this action enables the progression to cancer. 
 
HPV & Cervical Cancer 
HPVs are the most common sexually transmitted viruses. It is estimated that there are 
450,000 new cases of cervical cancer worldwide, 10 million cases of high grade dysplasia, 30 
million cases of low grade dysplasia and 300 million cases of cervical HPV infection without 
cytological abnormalities (15). About 200 000 women will die of cervical cancer each year. 
The mechanism of HPV carcinogenesis was first identified in cervical cancer. Worldwide, 
greater than 90% of cervical cancers are related to HPV infection. In a majority of these 
cases, high risk HPV types 16 and 18 have been implicated (16). 
 There are critical steps that have been identified in the path to HPV cervical 
carcinogenesis. (See Figure 1.3 HPV-associated cervical carcinogenesis). At younger ages, 
sexual transmission of HPV is extremely common. Most infections will clear quickly and 
approximately 90% are undetectable by 2 years. About 1/3 of infections will show concurrent 
minor or equivocal cytologic abnormalities. These abnormalities are not as predictive of 
cancer as is the type of HPV. Having a persistent, carcinogenic, high-risk type of HPV 
infection is highly associated with progression of infected cells to pre-cancer. Grade 3 
cervical intraepithelial neoplasia (CIN3) is a good surrogate of cancer risk, whereas CIN2 is 
more ambiguous. CIN3 can develop quickly after HPV infection. The small precancerous 
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lesions grow out slowly and initially may be difficult to observe by cytology or, especially, 
by colposcopy. The risk of invasions stretches over decades as the pre-cancers grow (17).   
 
 
 
 
 
 
 
 
Figure 1.3 HPV-Associated Cervical Carcinogenesis 
 
De Marco et al. show that HPV16 integration occurs in a subset of low grade cervical 
lesions, and that the quantitative RT-PCR method they used is a sensitive, reliable and 
specific technique, suitable for the identification of HPV16 integration. This technique 
allows the identification of the fusion region between viral and cellular DNA, followed by 
DNA sequencing. They detected and confirmed the presence of HPV integrated forms, even 
mixed with episomal forms, in pre-neoplastic cervical lesions. The evaluation of E2/E6 HPV 
ratio in one lesion is possible with this method. E2/E6 copy number ratio allows avoidance of 
technical problems which occur due to the co-existence of infected and not infected cells, 
without misinterpretation of type present (18).  
Munoz et al found that 15-20 types of HPV can cause cancer, but their carcinogenic 
strength varies greatly. HPV-16 and 18 account for approximately 70% of cancers worldwide 
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(15). Zuna et al utilized consensus polymerase chain reaction (PCR) to analyze  150 
cytology’s  and found that HPV-16 is the most likely type to cause high-grade squamous 
intraepithelial lesions (HSIL). Interestingly they also saw that HPV-18 caused relatively little 
HSIL even though it is found to play a prominent role in 20% of cancers (19). 
 
Oral & Genital Cancer Connection 
Oral-genital contact has been found epidemiologically to result in oral and cervical 
cancers within couples (20, 21). An analysis of the Swedish cancer registry data (1958-1996) 
showed that husbands of women with cervical cancer had a significantly increased risk of 
developing either tongue or tonsil cancer. Husbands of cervical cancer patients developed an 
excess (SIR over 2.00) of both tonsillar cancer (SIR 2.39 when wife with in-situ cancer and 
SIR 2.72 when wife with invasive cervical cancer) and cancer of the tongue. Also, women 
diagnosed with cervical carcinoma in-situ after the age of 50 were 2.58 times more likely to 
develop tonsillar cancer (20). Hisada, et al examined the incidence of second primary cancers 
occurring after cervical and anal cancer. Data from the Connecticut Tumor Registry for 
1935-1988 and eight other US tumor registries from 1973-1988 were used. Women with 
primary invasive cervical cancer had a relative risk of 4.6 (95% confidence interval (CI) 2.4-
8.1) for subsequent invasive anal cancer. Increased relative risks after cervical cancer were 
also found for cancers of the oral cavity (relative risk (RR) = 2.2) (22). A recent study 
looking at 1670 patients with oral cancer found that HPV16 was detected in most of the 
oropharyngeal cancers and the patients with tumors containing the HPV16 strain were three 
times more likely to report a history of oral sex than those with tumors that did not contain 
the virus (23). Specific sexual behaviors have been more strongly associated with risk of an 
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HPV-positive tumor, including a history of performing oral sex and oral-anal contact 
according to Gillison (24).  
The excess of tonsillar cancer among husbands of women with HPV-associated 
neoplastic lesions of the cervix as well as correlations with certain sexual habits supports the 
hypothesis that HPV may be involved in oral epithelial carcinogenesis. Many oral cancer 
studies have not focused on sexual habits as a contributing etiologic factor and this is an area 
to be incorporated into future studies to further characterize the association of oral and 
genital transmission of these types of cancers. 
 
HPV Infection & HNSCC  
The role of HPV in HNSCC has been examined in numerous epidemiologic studies. 
In a recent meta-analysis it was shown that the probability of detecting high-risk HPVs in 
HNSCC was 2.8 times greater than low-risk HPVs (25). A systematic review in 2005 by 
Kreimer determined that in the 5046 HNSCC specimens from 60 studies, the overall HPV 
prevalence was 25.9% (95% CI 24.7-27.2) and the prevalence in OSCC subset was 35.6% 
(95% CI 32.6-38.7) (26).  Another systematic review by McKaig showed that PCR could 
detect HPV in 34% (416/ 1205) of HNSCC in various studies (27).  Shiboski performed a 
study to determine what proportion of the population could be expected to have HPV in non-
tumor tissue and compared this to immunocompromised patients who are more likely to have 
opportunistic infections. They found that based on direct brushing of the tonsils from 
individuals without HNSCC, the prevalence of tonsillar HPV infection is 1% in non-
immunocompromised adults and up to 3% in individuals seropositive for the HIV (2).  
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A multi-center study published in 2003 by the International Agency for Research on 
Cancer (IARC) found that HPV appears to play an etiologic role in many cancers of the oral 
cavity.  They also found that the most common HPV type in genital cancers (HPV16) was 
also the most common in these oral tumors. Ringstrom et al investigated the presence and 
type of HPV infection in head and neck tumors to determine whether infection was 
associated with individual tumor characteristics, patients’ pattern of tobacco and alcohol 
exposure, or with clinical outcome. Using a case series of tumors located in the oral cavity 
and oropharynx a PCR-based technique with restriction fragment length polymorphism 
analysis was used to detect and type HPV. They found 18/89 (20%) had detectable HPV16 in 
their tumor samples. HPV16 was detected in 64% of tonsil tumors, 52% oropharyngeal 
tumors, and 5% oral cavity tumors. Also the mean age of subjects with HPV16-positive 
tumors was younger than the patients with HPV-negative tumors. The positive group 
consumed less alcohol on a weekly basis and had a better clinical outcome compared with 
the HPV-negative group (28).  
While these studies have provided the foundation to support HPV’s role in head and 
neck cancer there are many gaps that have not been addressed. Many of these previous 
studies failed to compare dysplastic and carcinomatous tissue with matched normal tissue 
and used molecular assays with varying sensitivities and specificities for viral detection. Also 
many of these studies only assessed what association there was between HPV and the entire 
head and neck and did not specifically analyze the association of HPV with oral cancer. To 
date there have been no studies looking at non smokers and non drinkers to determine the 
prevalence of HPV in this subset of oral cancer patients.  
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HPV Infection & Oropharyngeal Cancer 
The first reports of HPV in oral cancers came in the early 1980’s. Since then many 
studies have looked at HPV and its possible connection to the development of oral cancer 
and more specifically oropharyngeal cancer (OSCC). The role that HPV may play in OSCC 
has been controversial. The controversy relates mainly to the variable detection rate of HPV 
in these tumors, but this is due to the different sensitivities of various detection techniques, 
the type of specimen taken and its handling, as well as the population examined as many 
tumors are unquestionably tobacco-related. Also important was the sub-site examined. There 
appears to be different etiologies depending on the oral sites; for example lip cancer is 
undoubtedly related mainly to sun exposure (29). The human papillomavirus (HPV) DNA 
has been consistently detected in 20% of HNSCCs overall and in 50% of OSCCs (1). The 
following studies confirm this finding and support the hypothesis of HPV as an etiology in 
oral cancers. 
An important pathway in many cancers is the methylation of regions of DNA 
important in the progression of the cell cycle and this is a marker that is being looked at in 
cancers studies. The term DNA methylation refers to the transfer of a methyl group to 
cytosine residues, which are stably maintained at CpG dinucleotides (meCpGs). Methylated 
CpGs lead to the binding of transcriptional repressors, part of a network of epigenetic 
regulatory pathways. Balderas-Loaeza et al reports hypermethylation of the L1 gene and part 
of the long control region, a diagnostically important segment of the viral DNA, in 10 out of 
12 HPV-16 positive oral carcinomas from Mexican patients. These data indicate epigenetic 
changes of HPV-16 in oral carcinomas similar to those in anogenital carcinomas, suggesting 
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carcinogenic processes under the influence of HPV-16 in most if not all of these oral 
malignant lesions (30).  
A recent case-control study in Montreal, matched on age and gender, examined oral 
exfoliated cells from the buccal mucosa utilizing consensus PCR as well as serum based 
ELISA. 30% of their cases were non-smokers and 11% were non-drinkers.  HPV DNA was 
detected in 19% of cases (14 out of 72), and 5% of controls (six out of 129). Among tonsil-
related cancers (palatine tonsil and base of tongue) viral DNA was detected in 43% of cases 
(31).  Smith et al utilized oral exfoliated cells to look for HPV. The study had subjects 
expectorate after swishing with an oral rinse of saline 30sec and used PCR MY09/11 primer 
& dot blot hybridization to detect HPV. They found that 22.9% (201 cases) and 10% (333 
controls) of controls were HPV positive. They concluded that oral exfoliated cells were 
predictive of HPV types in tumor tissue (32).  
Dahlstrom et al designed the only study which compared smokers to non-smokers. 
They looked for the presence of HPV-16 antibodies in ever-smoker and never smoker 
patients matched on age (+/- 5 years), sex, and tumor site. Serum was assayed for HPV-16 
L1 virus-like particles by using an ELISA.  They found HPV-16 antibodies in 40.8% cases 
and 9.2% controls. Subjects with HPV-16 seropositivity was more common in never-smokers 
with HNSCC than in ever-smokers (43.3%rsus 38.3%, respectively), this difference was not 
statistically significant. They only used subject’s serum which has not been found to be as 
reliable a marker of HPV infection as the examination of tumor DNA and they did not look 
at alcohol as a confounding factor (33).  
An important case-control study by D’Souza et al looked at both smoker or drinkers 
and non smoker or nondrinkers as separate categories and found that HPV16 L1 
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seropositivity was highly associated with OSCC in heavy tobacco and alcohol users and was 
the same in OSCC patients without these risk factors. They also looked at oral HPV16 
infection by utilizing saliva and exfoliated cells in a real time PCR assay targeting the E6 
gene and found that OSCC was highly associated with HPV16 no matter what their tobacco 
and alcohol status was. This study also determined that tobacco and alcohol abuse was 
associated with HPV16 negative findings in OSCC’s.  Synergy was evaluated to determine if 
there was an increase in cancer risk when a subject was exposed to both HPV and was a 
heavy smoker and they found that there was no synergy between these two factors. They felt 
that this showed 2 distinct pathways in the development of OSCC (34).  
Previous studies have determined that HPV infection does play a role in orophayngeal 
carcinogenesis, yet significant gaps remain. The lack of adequate controls or consideration of 
confounding factors, varying methods of specimen sampling and small sample size need to 
be addressed in future study designs. Further there is a need to have a combined category of 
non-smokers and non-drinkers and compare to the smoker/drinker subset.   
In summary, since there is an alternative means of p53 silencing with the production 
of the E6 oncoprotein, the p53 sequence alterations, which are seen in most oral cancers of 
smokers and drinkers, are decreased in the setting of HPV infection. More importantly only a 
fraction of smokers and drinkers develop cancer, suggesting cofactors that include HPV or 
other infectious agents. HPV has been consistently detected in previous studies of oral 
cancers. Interpretation in a majority of previous studies has been limited by the following: 
the low copy number of HPV in OSCC, the failure to compare dysplastic and carcinomatous 
tissue with matched normal tissue, the use of molecular assays of varying sensitivities and 
specificities for viral detection, a lack of adequate controls or consideration of confounding 
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factors, and small sample size (25). We have addressed most of these limitations, but not all 
in our case-control study. Because of the causative link between HPV and squamous cell 
carcinomas, early identification of the virus may provide a crucial marker of high–risk 
susceptibility for developing these malignancies (35)  
We hypothesize that high risk HPV infection is a predominant independent risk factor 
in the development of oropharyngeal squamous cell carcinoma (OSCC), in patients who do 
not smoke or drink (NS/ND). Also as an infectious agent, these cancer associated HPV 
strains may be transmissible orally. The mechanism of transmission of HPV to the oral cavity 
warrants further investigation as well as the role it has played in the increase in tonsillar 
cancer. The long term goal of the following project was to determine the role of these 
mechanisms and to analyze the expression of HPV oncoproteins. To meet this goal we have 
developed the following specific aims.  
 
1.2 SPECIFIC AIMS 
AIM 1 To design a case-control study that identifies and enrolls patients diagnosed with oral 
cancer (cases) and benign tumors (controls) with no history of tobacco and/or alcohol use to 
determine whether high-risk HPV type 16/18 infection is significantly associated with OSCC 
in NS/ND. 
AIM 2 To determine concordance between HPV infection and the resultant OSCC in sexual 
partners with no other known risk factors.  
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CHAPTER 2 
Oropharyngeal Carcinomas In Non-Smokers And Non-Drinkers: A Role For HPV 
 
AIM 1: To design a case-control study that identifies and enrolls patients diagnosed with oral 
cancer (cases) and benign tumors (controls) with no history of tobacco and/or alcohol use to 
determine whether high-risk HPV type 16/18 infection is significantly associated with OSCC 
in NS/ND. Our working hypothesis is that OSCC’s of patient with no prior or current 
exposure to tobacco or alcohol will be infected with high risk HPV- types 16 and/or 18.  
 
 
 
 
 
 
Authors: Andrews E., Seaman T., Webster-Cyriaque J. 
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2.1 ABSTRACT 
Purpose: The incidence of oropharyngeal squamous cell carcinoma (OSCC) increased 3% 
annually from 1973-2001.  Most OSCC’s can be attributed to tobacco and alcohol, but 25% 
of OSCC patients have no known risk factors. Case-control studies of nonsmokers and 
nondrinkers (NS/ND) have not previously been performed. The primary objective of this 
study was to determine whether high-risk HPV infection was significantly associated with 
OSCC in NS/ND.  
Experimental Design: Utilizing the UNC Healthcare Cancer Registry (1995-2005), of 802 
patients with oropharyngeal cancer, 18 NS/ND cancer cases were identified.   Data were 
obtained from these individuals and 22 benign controls that were consecutively identified. 
Biopsy tissue from each individual was subjected to amplification and typing of conserved 
regions of the HPV genome. 
Results: Logistic regression analysis determined that cases were 6.1 (OR 95% CI, 1.3 – 28) 
times more likely to have HPV infection in their tumors than controls. High-risk HPV DNA 
was readily detected in the tonsils and base of tongue (oropharynx) of 14/18 cases and 6/22 
controls. Of the high-risk HPV containing lesions, 85% (17/20) of these originated in the 
oropharynx (chi- square, p=0.03).   High risk HPV was also detected in benign biopsies of 
the oropharynx in 30% (3/10) of individuals who had a previous oral cancer (p=0.006).      
Conclusions: The infectious nature of OSCC in NS/ND was revealed by consistent detection 
of HPV.  These data suggest HPV’s role in transforming oral epithelium, providing further 
evidence of the need to screen the oropharynx, specifically the base of tongue, for HPV in 
NS/ND.   HPV provides a crucial marker of high-risk susceptibility in this population. 
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2.2 INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity 
and mortality with 30,000 new cases in the US each year. While the incidence of HNSCC has 
remained stable, the incidence of oropharyngeal squamous cell carcinoma (OSCC), a subset 
of HNSCC, has increased 2% to 3% annually from 1973 to 2001(1). A more recent analysis 
of  SEER data analyzed sites where HPV has been consistently detected including, base of 
tongue, tonsils, lingual tonsil, and Waldeyer’s ring. These HPV related sites had an annual 
percentage change (APC) in cancer incidence of 5.22 (p<0.05) during 2000 to 2004 (2). 
OSCC has a high mortality rate and is characterized by a poor prognosis, with an overall 5 
year survival rate of 59.4%, accounting for approximately 8000 deaths/year in the US.  Many 
OSCCs can be attributed to exposures such as tobacco and alcohol, but there is a subset of 
patients who do not have either of these risk factors and still develop cancer (3). Also, only a 
fraction of smokers and drinkers develop cancer, suggesting cofactors that may include 
tumor viruses or other infectious agents as risk factors. 
Human papillomaviruses (HPVs) are DNA tumor viruses tropic for squamous 
epithelium with more than 120 different types identified to date. Low risk HPVs such as 
HPV-6 and 11 induce benign proliferation of the epithelium in the form of papillomas. In 
contrast, the high risk, oncogenic types, such as HPV 16 and 18, are found integrated in the 
host DNA.  The role of HPV- type 16 and 18 has been firmly established by their strong 
epidemiologic association as the etiological agent in cervical cancer (4).  The high-risk type 
HPV E6 and E7onco-proteins target the p53 and pRB tumor suppressor pathways rendering 
these pathways dysfunctional in the majority of HPV related human cancers.  
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High risk HPV DNA has been consistently detected in 20% of HNSCCs overall and 
in 50% of the OSCC subset (5).  It has been proposed that high risk type HPV infection has 
contributed to the increase in OSCC. To date, no studies have addressed HPV associated 
OSCC in non-smokers and non-drinkers. The purpose of this study was to determine whether 
high risk HPV infection is associated with OSCC in the non-smoking and non drinking 
population. 
 
2.3 METHODS & MATERIALS 
Subjects 
This study was approved by the School of Medicine, Institutional Review Board at 
the University of North Carolina at Chapel Hill (IRB# 05-DENT-1263-ORC). Study subjects 
were identified through the UNC Healthcare Cancer Registry which has been cataloging 
cases since their reference year, 1995 with more than 22,000 cases. This Cancer Registry 
maintains a database for all patients who have been diagnosed and/or treated for all 
malignant neoplasm’s at UNC Healthcare. Of the registered cases, there were 802 subjects 
who had a cancer in the oropharynx (tonsil and base of tongue) or the oral cavity proper.  61 
of these had no documented habit history in the database.  There were 458 of these subjects 
with a cancer in the oropharynx or oral tongue. Of the 741 registered subjects 68 were 
confirmed to be non-smokers and non-drinkers by chart review, and 47 of these had a lesion 
in the oropharynx or oral tongue.  Tissue samples were consecutively retrieved based on the 
site of their tumor in the following categories: tonsil, base of tongue, oral tongue. Samples 
were chosen based on date from 1995 - 2005, starting with subjects who had tissue more 
recently biopsied. Benign tonsil tissue was assayed from previous sleep apnea subjects 
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without a cancer history, other benign tissues (oral tongue) came from the UNC School of 
Dentistry Oral and Maxillofacial Pathology Archives. Informed consent and Health 
Insurance Portability and Accountability Act authorization were obtained. All cases and 
controls were selected based on having no prior or current use of tobacco or alcohol. Usage 
was confirmed by a chart review of all prospective subjects. Cases were subjects who had a 
histologically confirmed and diagnosed cancer, these comprised 2.3% of this registry subset. 
Controls were subjects who had a biopsy which was histologically confirmed and diagnosed 
as benign. A subset of the controls were subjects who had a previous history of OSCC and a 
subsequent benign biopsy.  
Sample Size Calculation 
Sample size was calculated by utilizing a two-sample comparison of proportions 
estimation.  Based on previous studies we estimated the proportion of exposed controls to be 
5% and the proportion of exposed cases to be 60% or greater. From this estimation it was 
determined that there should be 18 cases and 18 controls. Ten of the controls had a previous 
cancer history and12 controls had no cancer history, for a total of 22 controls. 
Histology 
Paraffin-embedded biopsy specimens were serially sectioned at a thickness of 5 μm 
and adhered to poly-L-lysine-coated slides for histological evaluation and confirmation of 
diagnosis by two independent pathologists. 
Preparation of Specimens 
Paraffin blocks containing tumor tissue from 40 patients were retrieved, 5 μm 
sections were deparaffinized and DNA extracted using the DNAeasy protocol from Qiagen 
(Valencia, Ca). Amplifiable quality of DNA was confirmed by a polymerase chain reaction 
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(PCR) assay targeting the human beta-actin, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or 18S genes(6).  HeLa cell, an immortalized HPV-18(+) cell line, was used as a 
positive control. All control samples were prepared and analyzed in parallel with the clinical 
specimens to ensure that proper reaction conditions were maintained. Special care was taken 
to control contamination. To detect possible DNA contamination, all tests included a 
negative control amplification containing double distilled, autoclaved, filtered, (ddH2O) and 
PCR reagents.  PCR assays were carried out using a dedicated PCR area for reaction setup, 
dedicated positive displacement pipettors and single use aliquots of all reagents including 
primers and enzyme. At least 2 replicates per sample were analyzed, and DNA from HPV 
negative tissue, fibroma, was interspersed as a negative control, to assure that issues of 
contamination were minimized. 
HPV- L1 Polymerase-Chain Reaction Assay 
All samples were then screened for the presence of HPV using a standard nested PCR 
assay, described elsewhere (7), consisting of the MY09/11 primer set (primary PCR) and the 
GP5+/6+ primer set (secondary PCR). These primers are consensus degenerate primers 
complementary to the conserved L1 region of HPV. (My9-
’CGTCCMARRGGAWACTGATC3’, My11 5’GCMCAGGGWCATAAYAATGG-3’, 
Gp5+ 5’TTTGTTACTGTGGTAGATACTAC3’, Gp6+ 5’GAAAAATAAACT 
GTAAATCATATTC3’) Nested PCR, employing degenerate consensus primers, has been 
shown to be a specific and extremely sensitive means of detecting a wide range of HPV 
types, 5-fold higher than that of one step PCR (8-10).  In the initial amplification, MY PCR 
detected a product size of ~450bp. Second step MY/GP PCR detected a product size of 
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~140bp. PCR products were separated by electrophoresis in a 2% agarose gel. To insure 
accuracy, all samples were tested in replicate (2-3 times).   
HPV 16/18 L1 Multiplex Real Time PCR Assay 
The DNA was employed for real-time PCR amplification of the L1 region of the HPV 
genome.  Briefly, DNA, Lightcycler TaqMan Master Mix (Roche) and the Roche Lightcycler 
480 detection system were used for amplification.  Detection of HPV16 L1 DNA was 
performed using HPV16L1F (5’TTGTTGGGGTAACCAACTATTTGTTACTGTT3’) and 
HPV16L1R (5’CCTCCCCATGTCGTAGGTACTCCTTAAAG3’) as primers and 
HPV16L1PROBE (5’6-FAM-GTCATTATGTGCTGCCATATCTACTTC-TAM3’) as a 
TAqMan probe. Detection of HPV18 L1 DNA was performed using HPV18L1F 
(5’ATCAATTATTTGTTACTGTGGTAGATACCACTCC3’) and HPV18L1R 
(5’GCTATACTGCTTAAATTTGGTAGCATCATATTGC3’) as primers and 
HPV18L1PROBE (5’HEX-GTCATTATGTGCTGCCATATCTACTTC-TAM3’) as a 
TAqMan probe.  The cellular Human APOB gene was amplified to ensure the quality of the 
DNAs using HAPBF (5’TGAAGGTGGAGGACATTCCTCTA3’) and HAPBR 
(5’CTGGAATTGCGATTTCTGGTAA3’) as primers and HAPBPROBE (5’CY5-
CGAGAATCACCCTGCCAGACTTCCGT-BHQ23’) as a TAqMan probe.  Analysis of the 
data was performed with the associated LightCycler 480 software (Roche). 
DNA Sequencing 
Specimens with amplification products visualized in the agarose gel of the expected 
size were considered positive for HPV. The PCR product of each sample was then purified 
with ExoSap-IT reagent (USB, Cleveland, Ohio, USA) followed by direct sequencing of the 
targeted HPV region using ABI Big Dye® terminator reagents (Applied Biosystems, Foster 
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City, CA) and an ABI PRISM 3730 DNA sequencer at the UNC Genome Analysis Facility. 
Amplimers were sequenced in both forward and reverse orientations. Sequences were 
compared using NCBI Blast2 software with EMBL entries for the human papillomavirus. 
Sequencing analysis was performed using the Vector NTI 10.1.1 software from Invitrogen. 
To perform this analysis DNA extracted sequences from all positive patient samples, HeLa, 
HPV-18 (Genbank-U89349), HPV-16 (Genbank-K02718) and Siha (Genbank-U89348), an 
HPV 16(+) cell line were utilized. A Guide Tree, which resembles a phylogenetic tree, in 
Vector NTI Advance was created using the Neighbor Joining method (NJ) of Saitou and Nei. 
The NJ method works on a matrix of distances between all pairs of sequence to be analyzed. 
These distances are related to the degree of divergence between the sequences. The Guide 
Tree was calculated after sequence alignment.  
Statistical Analysis            
Comparisons of general characteristics were made by Student t-test for continuous 
variables, and by Pearson’s Chi-square test for categorical variables. In all evaluations p 
values < .05 were considered statistically significant. Factors utilized for analysis include 
sex, age at diagnosis, race, high-risk HPV presence, tumor or biopsy location. Traditionally, 
OSCC’s arise in males older than 60 years of age, because of this age was analyzed as a 
dichotomous variable with the cut point of 60 years. A logistic regression model was used to 
evaluate the association between several factors and HPV status. To measure the association, 
the crude Odds Ratios (ORs) and the 95% Confidence Intervals (CIs) were calculated. 
Because of the small sample size of our study, the logistic regression model could only assess 
2 variables in the analysis. The 2 variables utilized in this analysis were the main outcome of 
interest, HPV infection and location of tumor/biopsy, as these are hypothesized to be 
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associated with malignancy. Computations were performed using STATA statistical software 
(Version 9.2, Statistics/Data Analysis, Stata Corp, College Station, Texas 77845 USA).  
 
2.4 RESULTS  
Of 741 individuals from the UNC health care registry with oral cavity or oropharynx 
cancer, 70 % were smokers and drinkers, 17% were smokers, 4% were drinkers and 9% were 
non smokers and non drinkers, without typical risk.   In this study of 40 non-smokers and 
non-drinkers there were 18 subjects with cancer (cases), 10 subjects with a previous cancer 
history and subsequent benign biopsy (controls) and 12 subjects with a benign biopsy and no 
previous cancer history  (controls).   Comparative analysis of subject characteristics 
determined that the mean age of the cases was 56, while the mean age of the controls with a 
previous cancer history was 59, and was 56 years in the subjects with no previous cancer 
history (Table 2.1).  With regard to distribution of sites biopsied, 89% of cancer subjects had 
their cancer originate in the oropharynx (tonsil and base of tongue) and, 36% of the controls 
had a benign biopsy from this region.  
DNA from paraffin embedded tissue was analyzed by two PCR methods.  A 
multiplex real time PCR, that utilized HPV L1 consensus primers and strain specific probes 
targeted to HPV16, 18, 6 and 11, was performed.  With the exception of seven benign 
subjects who were not tested with real time PCR, due to lack of tissue, all other tissues were 
analyzed in this way (Table 2.2).  Of the 18 cancers, 10 were found to harbor HPV 16 and 
three were HPV 18 positive.  Of the 10 patients with a previous cancer history 3 of 10 were 
HPV positive, 2 with HPV 16 and 1 with HPV 18.  Consensus degenerate PCR of the HPV 
L1 region in this population detected HPV in half of the subjects (20/40).  Amplimers from 
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all of those that were positive were sequenced and the results of the alignment analysis are 
found in Figure 1 and Table 2. Highly conserved HPV signature sequences were consistently 
detected and are highlighted. Consensus PCR found 78% (14/18) of the cancer subjects were 
HPV+ and all of these were high risk type (Table 2.3). High-risk type HPV16 was detected in 
thirteen of the subjects. Consistent with the HPV16 genotype, a 4 base pair deletion at 
coordinates 6677-6680 was detected in all of the HPV16 positive subjects and in the two 
HPV16 reference sequences. While this deletion was not detected in the HPV18 sequences, 
there was the characteristic CCTGG sequence only found in the HPV18 subjects and 
reference sequences. High-risk type18 was detected in seven of the subjects.  Interestingly, in 
the benign controls with a previous cancer history, 30% (3/10) had HPV in their base of the 
tongue biopsy tissue and all of which were high-risk type. In the control group, with no 
previous cancer history, 25% (3/12) were HPV 18+ and the origin of these biopsies was from 
the oral tongue and tonsils (Table 2.3).  
Comparison of consensus PCR, the gold standard, to real time targeting the same 
region detected complete concordance between real time and consensus PCR for HPV 16 and 
HPV 18 detection in both cases and controls.  Of the 14 that were HPV positive with 
consensus PCR, 13 showed concordant results for the high-risk HPV type detected by 
consensus PCR.   Three of the four cancer subjects which were negative with consensus PCR 
were negative with real time PCR. In the benign subjects, real time PCR detected the same 
type of HPV in 75% of subjects which were HPV positive with consensus PCR.  Of the 11 
benign subjects which were HPV negative by consensus PCR, three were HPV positive with 
real time PCR, perhaps reflecting differences in assay sensitivity level.  
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From the alignment analysis, a phylogenetic guide tree was developed utilizing the 
Neighbor Joining method. HPV 16 sequences originate on the same ancestral node on the left 
side of the tree (blue arrow) and are more similar to each other than to HPV 18 sequences. 
HPV18 sequences cluster at the middle right of the tree around the HPV18 L1 reference 
sequence and Hela, the HPV18 positive control (Figure 2.2). 
Characteristics that were significantly associated with high risk HPV infection 
included 1) having a cancer diagnosis and 2) a biopsy located in the oropharynx  as 
determined by chi square analysis (p value <0.05) (Table 2.4).  A logistic regression model 
was utilized to determine the odds of high-risk HPV infection in cancers of non-smokers and 
non-drinkers.  Results are summarized by adjusted ORs and corresponding 95% CIs. The 
analysis determined that NS/ND cancer subjects were 6.1 (95% C.I. 1.3 - 28) times more 
likely to have HPV infection, adjusted by biopsy location, than patients with a benign 
diagnosis. The confidence interval was wide due to the sample size, but was found to be 
significant p=0.02 (Table 2.4).  
 
2.5 DISCUSSION  
Today, it is generally agreed that viruses are implicated in 10 - 20% of all cancers, 
with DNA tumor viruses like HPV, often targeting the p53 and pRb tumor suppressor 
pathways to result in cell cycle alteration (12-14).  Greater than 90% of cervical cancers are 
related to HPV infection and in a majority of these cervical cancers, high-risk HPV types 16 
and 18 are implicated (15). Oral mucosa, especially oropharyngeal mucosa, is similar 
histologically to cervical mucosa. The presence of HPV in oral mucosa suggests that as in 
cervical cancer, HPV infection may also play a similar role in the transformation of oral 
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epithelium.  While it has been postulated that the path to cancer formation is a distinct multi-
step process, it also appears that there may be two major pathways leading to oral 
carcinogenesis - p53 mutation and DNA tumor viral pathogenesis (16). The transformation to 
cancer in the setting of HPV infection is distinct when risk factors, such as smoking and or 
drinking, are not present. The significance of infectious agents in oral cancers has not been 
fully demonstrated in persons without any known risk factors. 
 This study supports the hypothesis that high-risk HPV infection is a predominant risk 
factor in the development of oropharyngeal squamous cell carcinoma, in patients who do not 
smoke or drink.  The mean age of this study population was well below that of average, the 
age of most oropharyngeal cancer patients in the U.S. is over 65 years (11). Similar to other 
case-control studies we consistently detected HPV in OSCC (16-18).  We have shown for the 
first time that 78% (N=18) of NS/ND OSCC subjects had high-risk HPV in their tumors (p< 
0.006), predominantly HPV-type 16, as determined by sequence and subsequent 
phyolgenetic analysis and also using a novel HPV based real time assay.   The ability to 
multiplex provides a significant advantage when dealing with limited amounts of tissue or 
nucleic acid.  Further, the assay was equivalent to the gold standard in its detection of HPV 
in tumor tissues. 
High risk HPV types were associated with the oropharynx of cancer subjects and 
subjects with a previous cancer, but not in benign subjects.   The base of tongue and tonsil, 
that comprise the oropharynx, were consistently sites of malignancy.  Hence, location of 
infection is significant to development of malignancy in this population.  Many oral cancers 
originate in the base of the tongue and often go undetected, due to the location being difficult 
to view. High-risk HPV was detected in 30% (3/10) of subjects with a previous cancer 
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history, in follow up biopsies of the oropharynx that were deemed benign based on 
histopathology. Interestingly, all had a previous cancer in the same site as the subsequent 
negative biopsy.  Of the three, two of these originated from the base of the tongue and one 
from the tonsil.  High-risk HPV infection in the same location as the original cancer may 
heighten the potential for future recurrence in these individuals.  While high-risk HPV18 was 
detected in the tonsils of 2 benign subjects, the detection of high-risk HPV 18 in benign 
lesions was significantly lower, than in those with a previous cancer history. 
Examination of tumor tissue from both cases and controls revealed a significant 
association based on the origin of the tumor.   Of the cases in this study, HPV infection was 
detected in 5/6 cases with a cancer originating in the base of tongue. Clinically, the definition 
of oropharyngeal cancer must be extended beyond the tonsils to include base of tongue when 
looking for HPV infection.   D’Souza, et al. detected  high-risk HPV in oropharyngeal cancer 
samples of 72% (N=100) of their cases and determined that high-risk HPV was strongly 
associated with OSCC, regardless of exposure to established risk factors (16). In this study, 
consistent detection of HPV infection in the base of tongue highlights the importance of 
targeting other oropharyngeal regions for preventive screening/intervention even in those 
persons without traditional risk factors.  
Oral cancer patients with no exposure to smoking and/or drinking were 6.1 times 
more likely to have HPV DNA in there tumors than the NS/ND benign controls when 
adjusting for location.  This odds ratio is lower than those reported by case studies that 
examined HPV in association with traditional risk factors. Previous studies have shown a 
strong association of high-risk sexual practices with a resultant OSCC (16). These practices 
33 
 
were not examined by this study, but may be an important risk factor in the possible 
transmission of these infectious agents and should be addressed in future studies.   
Approximately 20% of adults become infected with HPV16 in their lifetime (20). 
Prophylactic HPV vaccines based on virus-like particles (VLPs) have been successfully 
tested in clinical trials. These vaccines are safe and effective in the prevention of persistent 
infection and subsequent pre-malignant cervical disease, and are now being introduced onto 
the market (20).  This case control study consistently detected HPV 16 and 18 in OSCC in 
78% of NSND cases, and most importantly oropharynx preponderance of 86%. We have 
identified close links between HPV and OSCC in NS/ND, this justifies the early 
identification of this virus and prevention if possible as this oncovirus may act as a crucial 
marker of malignancy susceptibility. The presence of HPV in orophayngeal cancers may 
warrant the use of vaccination in boys as well as girls 9-15 years of age, for oral cancer 
prophylaxis.  Identifying patients with persistent infection and treating them with close 
follow up is also important to reduce future cancers.  As HPV is associated with 1/5 of head 
and neck cancers, prophylaxis may result in a significant decrease in the incidence of disease.  
The revelation afforded by this report has significant public health implications and will be 
pivotal to the management and counseling of nonsmoking/non drinking oral cancer patients.   
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TABLES & FIGURES 
Table 2.1 Study Subject Characteristics  
(SD, standard deviation)  BX, biopsy 
 
 
 
 
 
 
CHARACTERISTIC CANCER 
(18/40)  
% (n) 
BENIGN W/ PREV 
CA (10/40) 
% (n) 
BENIGN 
W/OUT CA 
(12/40) 
% (n) 
MEAN AGE  56  (13.9 SD) 59 (15.8 SD) 56 (17 SD) 
         MALE  44 (8/18) 40 (4/10) 58 (7/12) 
        WHITE  89 (16/18) 80  (8/10) 75 (9/12) 
LOCATION OF BX:    
      TONSILS 56 (10/18) 40 (4/10) 33 (4/12) 
     BASE OF TONGUE 33 (6/18) 20 (2/10) 0 
     ORAL TONGUE 11 (2/18) 40 (4/10) 67 (8/12) 
HPV +  78 (14/18) 30 (3/10) 25 (3/12) 
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Table 2.2    HPV L1 Presence Detected by Consensus and Real Time PCR 
C
A
N
C
E
R
 
SAMPLE LOCATION L1 PCR 
 
L1 REAL TIME 
1A Tonsil HPV16 HPV16 
1B Tonsil HPV16 HPV16 
2A Tonsil HPV16 HPV16 
2B Tonsil HPV16 HPV16 
3 BOT HPV16 HPV16 
4 BOT HPV 16 HPV16 
7 BOT None HPV18 
9 BOT HPV 16 HPV16 
13 BOT HPV 16 HPV16 
18 Tonsil None NONE 
21 Tongue HPV18 NONE 
23 Tongue HPV16 HPV16 
35 Tonsil HPV18 HPV18 
36 Tonsil None NONE 
38 Tonsil None NONE 
39 Tonsil HPV18 HPV18 
40 Tonsil HPV18 HPV16 
51 BOT HPV16 HPV16 
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 SAMPLE LOCATION L1 PCR 
 
L1 REAL 
TIME 
BE
N
IG
N
 P
R
EV
 C
A
 
52 BOT HPV16 HPV16 
12 BOT HPV16 HPV16 
1A Tonsil None NT 
2A Tonsil None NT 
2B Tonsil None NT 
15 Tongue None NONE 
20 Tongue None NONE 
27 Tongue None NONE 
32 Tongue None NONE 
37 Tonsil HPV18 HPV18 
B
E
N
IG
N
 N
O
 C
A
 H
X
 
16 Tongue None NONE 
24 Tongue None NONE 
28 Tongue None NONE 
42 Tongue None HPV18 
45 Tongue None HPV18 
47 Tongue None NONE 
48 Tongue None HPV18 
50 Tongue HPV18 HPV18 
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 NT(Not Tested), None (No HPV Detected) CA(Cancer) HX(History) 
 
 
 
 
 
 
Table 2.3 Relationship of High Risk HPV Presence by Location & Diagnosis 
 
 
 
 
LOCATION L1 PCR 
 
L1 REAL TIME SAMPLE 
53 Tonsil None NT 
54 Tonsil None NT 
55 Tonsil  HPV18 NT 
56 Tonsil HPV18 NT 
CHARACTERISTIC  HPV + CANCER  
N =14  
HPV+ BENIGN W/ 
CA N=3  
HPV + BENIGN 
W/OUT N=3  
% HIGH/LOW RISK  100/0  100/0  67/33  
% OROPHARYNX  86  100  67  
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Table 2.4 Characteristics Associated with HPV Infection & Logistic Regression Model 
for OSCC in NS/ND  
 CHARACTERISTIC  HPV+  
%  (n)  
P 
VALUE 
LOGISTIC 
REGRESSION 
MODEL 
UNADJUSTED OR  
ADJUSTED OR 
(95%CI)  
AGE < 60 (30)  
AGE  > 60 (10)  
57 (17/30)  
30  (3/10)  
*0.1   
MALE (19)  
FEMALE (21)  
63 (12/19)  
38  (8/21)  
*0.1   
WHITE (33)  
OTHER (7)  
48 (16/33)  
57 (14/7)  
*0.7   
ORPHARYNX (26)  
ORAL CAVITY (14)
65 (13/26)  
21  (3/14)  
*0.008  9.6 (1.7 - 52.2)   
3.6 (0.7 – 19.1)  
CANCER (18)  
BENIGN W/CA (10)  
BENIGNW/OCA (12)
78 (14/18)  
30  (3/10)  
25  (33/12)  
*0.006   
HPV +  -----------  ---------  9.3 (2.1-39.9)  
6.1 (1.3 – 28)  
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Figure 2.1 Alignments of HPV L1 DNA sequences from cancer and benign biopsies of 
NS/ND.  Seven regions of HPV L1 signature sequence, highlighted in yellow, were detected 
in all positive samples.  A hallmark of HPV16 was a 3 base pair (BP) & 4 BP deletion in 
only the HPV 16 positive subjects. 
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Figure 2.2 Phylogenetic Analysis of HPVL1 Sequences from NS/ND. Phylogenetic 
analysis shows distinct ancestry by HPV type. HPV16 types originate from one ancestral 
node and the HPV 18 sequences are similar to each other and least related to the HPV16 
types.  
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CHAPTER 3 
Concurrent HPV-Associated Tonsillar Carcinoma In Two Couples 
 
AIM 2: To determine concordance between HPV infection and the resultant OSCC in sexual 
partners with no other known risk factors. Our working hypothesis is that HPV, as an infectious 
agent, is associated with tonsillar cancer transmission between sexual partners. 
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3.1 ABSTRACT 
Background: Human papillomavirus (HPV), the primary etiological factor implicated in 
most cervical cancers, has led to recent development of a HPV vaccine. Oral-genital contact 
has been shown epidemiologically to result in oral and cervical cancers within couples. 
Concurrent oral cancers in partners with close proximity have not previously been described. 
This report describes HPV in two couples with no smoking or drinking history, yet 
developed tonsillar cancer within 12 months of each other.   
Methods: After histopathologic evaluation, DNA was extracted from biopsy tissue of both 
couple members. HPV presence was identified by amplification of the L1, E6 and LCR 
regions, with subsequent sequence alignment and phylogenetic analysis of sequenced 
amplimers. A real time assay targeting the HPV16 and 18 L1 & E7 regions was performed.  
Results: Tissue samples from each couple member were positive for HPV-16, the most 
prevalent type found in other HPV-associated cancers.  HPV DNA sequences of the couples 
showed distinct inter-couple nucleotide differences and multiple unique intra-couple 
similarities. Sequences were also phylogentically unique when compared to other HPV + 
cancer samples.  
Conclusions: This report demonstrates, for the first time, detection of matching strains of 
HPV16 in two couples with concurrent development of tonsillar carcinoma in the absence of 
other risk factors, revealing the potential infectious nature of oropharyngeal cancer.  HPV 
presence in tonsillar cancers suggests its similar role in transforming oral epithelium, 
providing further evidence of the need to vaccinate men and women. 
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3.2 INTRODUCTION 
The link between viruses and cancer was a pivotal discovery in cancer research. 
Today, it is generally agreed that viruses are involved in 10 - 20% of all cancers, with these 
organisms often targeting the p53 and pRb tumor suppressor pathways, resulting in cell cycle 
alteration (1). HPV transmission has consistently been associated with cancer development. 
Oropharyngeal cancer, which includes cancer of tonsils, base of tongue, posterior pharynx, 
and soft palate, traditionally affects males over the age of sixty.  The five-year survival rate is 
approximately 20% with a 45% recurrence rate (2). Most oropharyngeal squamous cell 
carcinomas (OSCC) can be attributed to exposures such as tobacco and alcohol abuse, but a 
subset of younger patients who have neither of these risk factors still develop cancer, 
suggesting cofactors that include infectious agents, may be responsible for malignant 
transformation.  
An analysis of the Swedish Cancer Registry data (1958-1996) showed that husbands 
of women with cervical cancer had a significantly increased risk of developing either tongue 
or tonsillar cancer. This study identified 124 men who had upper aerodigestive tract cancers 
after their wives were diagnosed with invasive cervical cancers, as well as 325 men 
diagnosed with upper aerodigestive cancer after their wives had a diagnosis of in-situ 
cervical cancer. Moreover, women diagnosed with cervical carcinoma in-situ after the age of 
50 had a SIR of 2.58 for developing tonsillar cancer (3).  
A recent study looking at 1670 patients with oral cancer found that HPV16 was 
detected in the majority of the oropharyngeal cancers and that patients with tumors 
containing HPV16 were 3 three times more likely to report a history of oral sex than those 
with HPV (-) tumors (4).  HPV DNA has been consistently detected in 50% of oropharyngeal 
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carcinomas, of which the tonsils are a subset (5). While the above epidemiologic studies 
demonstrate that oral genital contact may result in oral and cervical cancers within couples, 
concurrent oral cancers in partners with close proximity have not previously been described, 
nor has the link to HPV been established in the resultant malignancies. This report describes 
HPV in two couples that did not have a smoking or drinking history, yet developed tonsillar 
cancer within 12 months of each other.  
 
3.3 CASE REPORT 
 Four patients presented to the UNC Hospital Dental clinic as part of their pre-
treatment for their respective tonsillar cancers. All expressed an interest as to the etiology of 
their cancer and the fact that their intimate partner had also been diagnosed with the same 
cancer. Once these patients were identified, they were consented to allow further examination 
of their tumors for possible HPV infection. Their case histories are as follows: 
A 58-year-old female, patient 1A, underwent evaluation for a neck mass with no 
symptoms of dysphagia or odynophagia and no history of smoking or drinking. She was 
treated with antibiotics without resolution. A fine needle aspiration (FNA) followed by a 
direct laryngoscopy with biopsy led to a diagnosis of T1N2bM0 squamous cell carcinoma 
(SCCA) of the right tonsil. Treatment with chemoradiation was completed 3 months after the 
diagnosis and at 39 months after diagnosis she has no evidence of recurrent disease. One year 
after her presentation, her 56-year-old spouse of 10 years, patient 1B, presented with right 
neck adenopathy concurrent with the diagnosis of stage 1 follicular, predominantly small 
cleaved type, intestinal lymphoma. FNA of the neck node led to a diagnosis of a synchronous 
T1N2aM0 squamous cell carcinoma of the right tonsil, treated with concurrent 
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chemoradiation followed by a neck dissection. The lymphoma required no active treatment 
and 24 months after diagnosis he had no evidence of recurrent tonsillar carcinoma. Patient 
1B smoked only minimally in high school and has no history of drinking.  
A 57-year-old non-smoking, non-drinking male, patient 2A, presented with right neck 
adenopathy unresolved with antibiotic therapy. He was diagnosed with a T2N2bM0 
squamous cell carcinoma of the right tonsil and was treated with concurrent chemoradiation. 
Seventeen months after diagnosis he has no evidence of recurrent tonsillar carcinoma.  His 
long term partner, patient 2B, a 51-year-old non-smoking, non-drinking female, presented to 
another hospital a few months after patient 2A was diagnosed with a neck mass. She was 
found to have a T2N1M0 squamous cell carcinoma of the left tonsil that was treated with a 
left neck dissection and postoperative radiation. Sixteen months after presentation there was 
no evidence of recurrent disease. 
 
3.4 METHODS 
Preparation of Specimens 
This study was approved by the School of Medicine, Institutional Review Board at 
the University of North Carolina at Chapel Hill.  Informed consent and Health Insurance 
Portability and Accountability Act authorization were obtained from the patients. Paraffin 
blocks containing tumor tissue or contra lateral benign tonsil tissue were retrieved. Five μm 
sections were deparaffinized and DNA was extracted using the DNAeasy protocol from 
Qiagen (Valencia, Ca). Amplifiable quality of DNA was confirmed by a polymerase chain 
reaction (PCR) assay targeting the human beta-actin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) or 18S genes(6). HeLa cell, an immortalized HPV-18(+) cell line, 
48 
 
was used as a positive control. All control samples were prepared and analyzed in parallel 
with the clinical specimens to ensure that proper reaction conditions were maintained. 
Special care was taken to control contamination. To detect possible DNA contamination, all 
tests included a negative control amplification containing double distilled, autoclaved, 
filtered water (ddH2O), and PCR reagents.  PCR assays were carried out using a dedicated 
PCR area for reaction setup, dedicated positive displacement pipettors and single use aliquots 
of all reagents including primers and enzyme. At least 3 replicates per sample were analyzed, 
and DNA from HPV negative tissue, fibroma, was interspersed as a negative control, to 
assure that issues of contamination were minimized. 
Polymerase-Chain Reaction Assay 
All samples were then screened for the presence of HPV using a standard nested PCR 
assay, described elsewhere, consisting of the MY09/11 primer set (primary PCR) and the 
GP5+/6+ primer set (secondary PCR) (7-10). These primers are consensus degenerate 
primers complementary to the conserved L1 region of HPV. Primers utilized for 1st step 
were: My9-5’CGTCCMARRGGAWACTGATC3’, My11 5’GCMCAGGGWCATAA.  In 
the initial amplification, MY PCR detected a product size of ~450bp.  Primers utilized for 
2ndstep were: Gp5+5’TTTGTTACTGTGGTAGATACTAC3’, 
Gp6+5’GAAAAATAAACTGTAAATCATATTC3’.  Second step MY/GP PCR detected a 
product size of ~140bp.  
PCR was also performed targeting the E6 and LCR regions described elsewhere (11). 
Primers utilized in a nested PCR were as follows for E6: 1st step F-
5’CGTAACCGAAATCGGTTGAAC3’, R-5’GGACCATCTATTTCATCCTCCT3’, 2ndstep: 
F-5’CGTAACCGAAATCGGTTGAAC3’, R-5”GCTCATAACAGTAGAGATC3’.   
49 
 
For the LCR region the primers were:  F-5’CTTGTGTAACTATTGTGTCATGC3’, 
R-5’AGTTGCTTGTAAATGTGTAACCC3’,F-5’CAACACCTACTAATTGTGTTGTGG3’, 
R -5’AAATCGGTTTGCACACACCCATGT3’.  
HPV-E2 PCR was also performed using the following primers: F-
5’CTTGGGCACCGAAGAAACAC-3’and  R-5’TTGGTCACGTTGCCATTCAC3’.  
All PCR products were then separated by electrophoresis in a 2% agarose gel. To 
insure accuracy, all samples were tested in replicate (3-4 times). 
DNA Sequencing 
Specimens with amplification products visualized in the agarose gel of the expected 
size were considered positive for HPV. The PCR product of each sample was then purified 
with ExoSap-IT reagent (USB, Cleveland, Ohio, USA) followed by direct sequencing of the 
targeted HPV region using ABI Big Dye® terminator reagents (Applied Biosystems, Foster 
City, CA) and an ABI PRISM 3730 DNA sequencer at the UNC Genome Analysis Facility. 
Amplimers were sequenced in both forward and reverse orientations. Sequences were 
compared using NCBI Blast2 software with EMBL entries for the human papillomavirus. 
Sequencing analysis was performed using the Vector NTI 10.1.1 software from Invitrogen. 
To perform this analysis DNA extracted sequences from all positive patient samples, HeLa, 
HPV-18 (Genbank-U89349), HPV-16 (Genbank-K02718) and Siha (Genbank-U89348), an 
HPV 16(+) cell line were utilized. A Guide Tree, which resembles a phylogenetic tree, in 
Vector NTI Advance was created using the Neighbor Joining method (NJ) of Saitou and Nei. 
The NJ method works on a matrix of distances between all pairs of sequence to be analyzed. 
These distances are related to the degree of divergence between the sequences. The Guide 
Tree was calculated after sequence alignment.  
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Real Time PCR  
The DNA was employed for real-time PCR amplification of the E7 and L1 region of 
the HPV genome.  Briefly, DNA, Lightcycler TaqMan Master Mix (Roche) and the Roche 
Lightcycler 480 detection system were used for amplification.  Detection of HPV16 E7 was 
performed using HPV16E7F (5’CTGTTATGAGCAATTAAATGACAGC3’) and 
HPV16E7R (5’CCAGCTGGACCATCTATTTCA3’) as primers. Detection of HPV18 E7 
was performed using HPV18E7F (5’CTGTTATGAGCAATTAAATGACAGC3’) and 
HPV18E7R (5’CCAGCTGGACCATCTATTTCA3’) as primers.  Probes for E7 detection 
were selected from a FAM labeled Human Universal Probe Library (Roche).  Probe 63 (cat. 
no. 04688627001) was used for HPV16 E7 detection and probe 6 (cat. no. 04685032001) 
was used and for HPV18 E7.   
Detection of HPV16 L1 DNA was performed using HPV16L1F 
(5’TTGTTGGGGTAACCAACTATTTGTTACTGTT3’) and HPV16L1R 
(5’CCTCCCCATGTCGTAGGTACTCCTTAAAG3’) as primers and HPV16L1PROBE 
(5’6-FAM-GTCATTATGTGCTGCCATATCTACTTC-TAM3’) as a TAqMan probe. 
Detection of HPV18 L1 DNA was performed using HPV18L1F 
(5’ATCAATTATTTGTTACTGTGGTAGATACCACTCC3’) and HPV18L1R 
(5’GCTATACTGCTTAAATTTGGTAGCATCATATTGC3’) as primers and 
HPV18L1PROBE (5’HEX-GTCATTATGTGCTGCCATATCTACTTC-TAM3’) as a 
TAqMan probe.  The cellular Human APOB gene was amplified to ensure the quality of the 
DNAs using HAPBF (5’TGAAGGTGGAGGACATTCCTCTA3’) and HAPBR 
(5’CTGGAATTGCGATTTCTGGTAA3’) as primers and HAPBPROBE (5’CY5-
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CGAGAATCACCCTGCCAGACTTCCGT-BHQ23’) as a TAqMan probe.  Analysis of the 
data was performed with the associated LightCycler 480 software (Roche). 
Histology 
Paraffin-embedded biopsy specimens were serially sectioned at a thickness of 5 μm 
and adhered to poly-L-lysine-coated slides and stained with hemotoxylin and eosin for 
histological evaluation and confirmation of diagnosis by two independent pathologists.                                  
 
3.5 RESULTS 
Biopsy tissues from each member of the couples, histologically diagnosed as 
squamous cell carcinoma, exhibited koilocytes typical of HPV infection and features typical 
of malignancy including abnormal mitotic figures, increased nuclear/cytoplasmic ratio, 
keratin pearls and invasion into underlying submucosa (Figure 1).   
Subsequent to histologic confirmation, DNA was extracted from the same paraffin 
blocks and PCR proceeded with HPV L1 specific consensus primers yielding a 140bp 
product, from all 4 patients similar to the Hela (+) control with no band present in the 
negative control.  HPV status was determined in contra lateral benign tonsil and malignant 
tissue from each couple member (Figure 2. Panel A. Representative Gel).  Tumors from 
couple 1 were consistently HPV positive while benign tissue for 1A was consistently 
negative. Benign tissue from 1B was unavailable as the block had been exhausted. 
Amplification from tonsillar tumor tissue of couple 2, as well as the lymph node from patient 
2B, were also HPV +. These data are representative of at least three replicates. While benign 
contra lateral tonsils from both members of couple 2, were consistently negative in each of 
three replicates (Figure 2 Panel B).      PCR products were sequenced in replicate in both 
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forward and reverse orientation and compared using NCBI Blast2 software. All tumor 
samples from the 4 patients showed a 94-97% match with the HPV type-16 reference 
sequence. Lymph node tissues of patient 2B were HPV-16 positive as well, with 97% 
identity to the HPV 16 Blast reference.   
Comparative genomics of epidemiologically varied HPV isolates from these tonsillar 
cancers indicated low sequence diversity overall. For direct comparison, multiple alignment 
analysis was performed using sequences from Couples 1 and 2, HPV 18 and HPV16 
reference sequences, and HPV positive cell lines SiHa and HeLa (Figure 3). Alignment 
revealed significant sequence identity between patients 1A and 1B and between 2A and 2B 
as well as between HPV16 reference and SiHa sequences. The analysis also exhibited distinct 
differences between the two couples and control sequences. There were differences between 
the 2 couples at base pairs 6685, 6695, 6774, 6776, 6777, 6779 (Figure 3Panel A).  While 
sequences from couple 2 were highly similar to SiHa, there was consistent distinction at 
coordinates 6657, 6659, 6661, 6666, 6681, 6775-6777, and 6780.  
To gain insight into HPV evolution within these tumors, we aligned a 200bp section 
(nucleotide positions ~6650 to ~6850) of each couple member and 14 other HPV positive 
oral cancers from the UNC Healthcare Cancer Registry, to construct a rooted tree using the 
Vector NTI Align X module. The phylogenetic method enabled systematic organization by 
genotype. The phyolgram generated from these data showed that while the HPV positive 
sequences from these couples were similar to each other, within each couple, (1A and 1B) 
and  (2A and 2B) sequences were equidistant from each other (data not shown).  Hence, the 
intra-individual differences were comparable to intra-couple difference with regard to 
distance.   While Couple 1 was phylogenetically similar to couple 2, their branches were 
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distinct. Couple 2 showed an ancestral node that was closer to HPV 16 reference sequences 
(Figure 3 Panel B).  HPV 18 and HeLa sequences were most distantly related. When 
comparing the sequences from each couple to the 14 other HPV (+) oral cancers from the 
UNC Healthcare Cancer Registry, the couple sequences were clearly distinct from the other 
oral cancers displaying unique intracouple changes. E2 PCR detected an intact E2 region in 
the lymph node tissue of subject 2BLN indicating at least one copy of episomal HPV. Intact 
E2 regions were not detected in any of other cancer tissues indicating that HPV was  
integrated into host DNA  within tissues from 1A, 1B, 2A and 2B. PCR targeting the E6 
region of HPV detected similar sequences of E6 in 3 of the four subjects, each of these were 
of German/European ancestry (Figure 4). E6 was not detected in  1A by consensus PCR 
perhaps due to low copy number within this paraffin embedded tissue or DNA fragmentation 
secondary to  DNA extraction.  LCR consensus PCR was performed on all samples yielding 
multiple sequence similarities and a solitary G to A base pair change within the YY1 binding 
site at nucleotide 7521 within couple 2 that was distinctly different from 7521 A in couple 1. 
Patient 2B had multiple additional nucleotide changes between coordinates 7620 and 7684.  
Real time PCR analysis targeting the E7 and L1 HPV regions confirmed the 
consensus PCR analysis in multiple assays (Figure 6).  All 4 partners were HPV 16 (+) with 
both of these probes and negative with the HPV 18 probe. When analyzing viral load through 
quantitative real time PCR, subject 2B had consistently higher viral load as compared to the 
other three subjects. This patient had a metastasis to her lymph node and more extensive 
disease than the other 3 subjects.  
Collectively, these results support interpersonal spread of HPV between individuals 
in each couple as the potential etiologic agent in the development of tonsillar cancer. 
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3.6 DISCUSSION 
The two couples cited in this report did not have a smoking or drinking history, and 
they developed tonsillar cancer within 12 months of each other. Tissue samples from each 
couple member were positive for HPV-16, the most prevalent type found in other HPV-
associated cancers.  The DNA sequences of 4 HPV 16 regions were detected in all 4 of these 
patients further showing the infectious nature of their respective cancers. HPV DNA 
sequences from these two couples showed distinct inter-couple nucleotide differences and 
multiple intra-couple similarities. Within the LCR region, at the YY1 binding site, there was 
a mutation at nucleotide 7521 within couple 2 that was distinctly different from 7521 in 
couple 1. Previous studies of cervical cancer have shown that deletions or mutations of  
YY1-binding sites play a significant role in over-expression of viral oncogenes and tumor 
progression (11-13). 
Within the 200bp L1 segment that was analyzed, 7 inter-couple variations were 
detected upon alignment. By definition greater than 10% sequence variation in the L1, E6 or 
E7 regions results in a different type of HPV.    In 1995, Yamada et al studied HPV type 16 
variant lineages in the United States. Of 3,690 nucleotide positions analyzed, several amino 
acid differences in the L1 region were determined between five distinct phylogenetic 
branches of HPV 16 lineages (14). Our subjects had similar changes to the European/German 
HPV 16 variant. Also within the L1 region the nucleotide changes were similar to an African 
variant in both couples. 
Analysis of polymorphisms within the E6 region detected a G to T change at position 
350.  This E6 associated nucleotide change as been associated with enhanced persistence of 
infection, and diminished differentiation potential, both necessary for transformation (15).   
55 
 
In this study, we also consistently detect a C to G at nucleotide 315, perhaps also associated 
with pathogenesis.  
Integration status was assessed and it was shown that all 4 patients had integrated 
HPV in their primary tumors. Patient 2B had integrated HPV in their primary tumor and 
nonintegrated HPV in the metastasis. A study by D’Marco et al showed that cervical 
neoplasias can have both integrated and nonintegrated, episomal forms of HPV as well as 
more than one type of HPV (16). This study supports our findings of having episomal and 
integrated forms of HPV in one lesion.  The sequence variance data form a basis for 
considering HPV16 sequence variations in the development of HPV16 L1-, L2-, or E6-based 
vaccine strategies, as correlates of cervical disease risk, and as tools for studying 
epidemiological issues such as viral persistence and transmission. There have been reports of 
multiple high-risk types of HPV infection in malignancies as well as mutation of the virus 
within infected malignant tissue (14, 17, 18). This may account for differences detected upon 
sequence comparison of the couples studied in this report.  
Approximately 20% of adults become infected with HPV16 in their lifetime (19). The 
concurrent presentation of HPV 16 associated tonsillar cancer in two couples implies 
transmission from one partner to another. Because of the causative link between HPV and 
squamous cell carcinomas, early identification of the virus may provide a crucial marker of 
high-risk susceptibility for developing these malignancies (20). Prophylactic HPV vaccines 
based on virus-like particles (VLPs) have been successfully tested in clinical trials. These 
vaccines are safe and effective in the prevention of persistent infection and subsequent pre-
malignant cervical disease, and are now being introduced onto the market (19). The presence 
of HPV in orophayngeal cancers warrants use of vaccination in boys as well as girls 9-15 
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years of age, for oral cancer prophylaxis.  As HPV causes 1/5 of head and neck cancers, 
prophylaxis may result in a significant decrease in the incidence of disease.  The revelation 
afforded by this report has significant public health implication and will be pivotal to the 
management and counseling of HPV infected cancer patients.   
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FIGURES 
1A. 
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1B. 
 
 
 
Figure 3.1 Histologic changes consistent with tonsillar carcinoma were detected in each 
couple member. Panel A. H&E stained tonsillar squamous cell carcinoma from patient 1A 
and 1B. Panel B. H&E stained tonsillar squamous cell carcinoma from patient 2A and 2B. 
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2A. 
 
 
2B. 
SAMPLE  # PCR  # (+)  # (-)  SEQUENCED  BLAST  
1A TUMOR  3  3  0  2 FOR/2 REV  HPV 16  
1B TUMOR  4  3  1  4 FOR/3REV  HPV 16  
2A TUMOR  3  3  0  2 FOR/2 REV  HPV16  
2B TUMOR  3  3  0  2 FOR/1 REV  HPV 16  
2LN  3  3  0  2 FOR/2 REV  HPV16  
1A BENIGN  3  1  2  1 FOR /1REV  No Match  
2A BENIGN  3  0  3  1 FOR/1 REV  No Match  
2B BENIGN  3  0  3  2 FOR /2 FOR  No Match  
 
Figure 3.2 Detection of HPV in Tonsil Tumors by nested PCR. Panel A. Matched normal 
and tumor tissue from couples 1 and 2 were assayed, patient 1A (Lane-1 benign, lane-2 
tumor) and from patient 2B (lane-4 benign, lane-5 tumor), are shown.  Tumor tissues yielded 
the expected 140bp product.  Lane-6 (+) Hela control, Lane 7- 100bp ladder.  Panel B. Table 
of Replicate PCR/Sequencing results. 
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3A. 
 
 
3B. 
 
 
Figure 3.3 Sequence alignment & phylogenetic tree of HPV L1 DNA from both couples 
shows intra-couple similarities and inter-couple differences. Panel A.  Shows 11 inter-couple 
differences highlighted with the red arrows. Areas highlighted in yellow are HPV signature 
sequences and are highly conserved regions. Panel B. Phylogenetic analysis shows couple 
one sequences have a distinct ancestral node and are most closely related to each other and 
not to couple 2. Couple 2 sequences are highly similar to each other and to Siha, referent 
sequence. 
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Figure 3.4 HPV E6 DNA from Couples Shows Intra-Couple Similarities And Inter-
Couple Difference.  The yellow regions are highly conserved signature sequences of HPV16 
only. The green sequence shows a distinct difference between 1B and couple 2A & 2B. The 
blue region is where 1B, 2A, & 2B differ from the referent. 
 
 
 
 
 
Figure 3.5 Alignment of HPV LCR Region Shows Intra-Couple Similarities & Inter 
Couple Differences.  Yellow highlighted areas are conserved region of HPV16 LCR. Blue 
highlight are partially similar regions and white are differences. 2A & 2B have one BP 
change that is different from 1A & 2B.  
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Figure 3.6 Quantitation of HPV 16 Viral DNA in Couples By Real Time PCR.  Panel A.  
HPV 16 E7 was detected in all 4 subjects with 2B having the highest viral load. Panel B. 
HPV 16 L1 was detected in all 4 subjects with 2B having the highest viral load. 
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 CHAPTER 4 
CONCLUSIONS 
 
4.1  
Cancers of the oral cavity and of the oropharynx are a major health problem 
worldwide, accounting for over 300,000 incident cases annually (1).  Today, it is generally 
agreed that viruses are involved in 10 - 20% of all cancers, with these organisms, like HPV, 
often targeting the p53 and pRb tumor suppressor pathways resulting in cell cycle alteration 
(2). The role of human papillomavirus (HPV) in the etiology of cervical and other anogenital 
cancers is now firmly established (3). Greater than 90% of cervical cancers are related to 
HPV infection and in a majority of these cervical cancers, high-risk HPV types 16 and 18 are 
implicated (4). Oral mucosa, especially oropharyngeal mucosa, is similar histologically to 
cervical mucosa and the presence of HPV in oral mucosa suggests HPV infection plays a 
similar role in the transformation of oral epithelium as it does in cervical cancer.  
This study supports the hypothesis that high-risk HPV infection is a predominant 
independent risk factor in the development of oropharyngeal squamous cell carcinoma, in 
patients who do not smoke or drink. We have shown that 78% (N=18) of NS/ND OSCC 
subjects had high-risk HPV in their tumors, predominantly HPV-type 16, the most prevalent 
type found in other HPV-associated cancers. It was also determined that 3 of the benign 
subjects had high-risk HPV in their tumor biopsy. Interestingly 2 of these control subjects 
had their biopsy originate from the base of the tongue and had a previous cancer in the same 
site. In the benign controls, without a previous cancer history, we found 2 subjects with high-
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risk HPV type 18 in their tonsillar biopsy and only one oral cavity control subject had low-
risk HPV. Most of the focus in previous studies has been identifying HPV in tonsillar cancer 
and not base of the tongue. The finding of HPV infection in the base of tongue shows the 
need to look beyond the tonsillar region to other areas in the oral cavity for these types of 
cancers. 
A recent study by D’Souza, et al also found high-risk HPV 16 DNA in OSCC, with 
high-risk HPV in 72% (N=100) of affected subjects. D’Souza also compared the OSCC 
subject’s brush biopsies to tonsillar brush biopsies of control subjects.  From this they found 
oral HPV infection to be strongly associated with OSCC regardless of exposure to 
established risk factors (5). No comparisons of the oropharynx to other oral cavity locations 
were made. Our data shows similar findings to D’Souza and are consistent with other case-
control studies (1, 5, 6). Our case-control study is the first to focus on NS/ND subject in the 
oropharynx and oral cavity.  We examined formalin fixed, paraffin embedded tumor tissue of 
both cases and control, utilizing subject biopsies from the oropharynx, as well as the oral 
cavity and from this design there was a significant association based on the origin of the 
tumor.  
Orophaynx cancer patients with no exposure to smoking and/or drinking were 6.1 
times more likely to have HPV DNA in there tumors than the NS/ND benign controls when 
adjusting for location. Previous studies have shown a strong association of high-risk sexual 
practices with a resultant OSCC (5). This was not a characteristic analyzed in this study, but 
plays an important role in the possible transmission of these types of cancers and should be 
addressed in future studies.  Also, our study was limited to assessing HPV infection through 
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the highly sensitive and specific nested PCR and a quantitative real time assay, but 
confirmation with other techniques such as in-situ PCR could strengthen the findings.  
For the first time ever our sub-study, analyzing tumors from intimate partners 
detected identical strains of integrated HPV 16 within each couple.  The two couples cited in 
this report did not have a smoking or drinking history, and they developed tonsillar cancer 
within 12 months of each other. Tissue samples from each couple member were positive for 
HPV-16, the most prevalent type found in other HPV-associated cancers.  HPV DNA 
sequences from these two couples showed distinct inter-couple nucleotide differences and 
multiple intra-couple similarities. Within the 200bp segment that was analyzed, 7 inter-
couple variations were detected upon alignment. By definition greater than 10% sequence 
variation in the L1, E6 or E7 regions results in a different type of HPV. In 1995, Yamada et 
al (7), studied HPV type 16 variant lineages in the United States. Of 3,690 nucleotide 
positions analyzed, several amino acid differences in the L1 region were determined between 
five distinct phylogenetic branches of HPV 16 lineages. There have been reports of multiple 
high-risk types of HPV infection in malignancies as well as mutation of the virus within 
infected malignant tissue (7-9).  This may account for differences detected upon sequence 
comparison of the couples studied in this report.  
The concurrent presentation of HPV 16 associated tonsillar cancer in two couples 
implies transmission from one partner to another. This is the first report to date of concurrent 
HPV associated tonsillar cancer in two couple. There clearly could be many unidentified 
similar couples. Future studies should incorporate this possible link as a way to identify 
others who are at risk. 
4.2 FUTURE DIRECTIONS 
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The findings of HPV associated OSCC show the need for future case-control studies 
comparing NS/ND to S/D with tumor categories which should include the oropharynx, 
specifically the base of tongue and tonsils and the oral cavity proper. The findings of HPV + 
tumors in the base of tongue sub-site is an important finding as this shows that clinicians 
should not be looking for HPV in the tonsils only, but in this other important location as well. 
The increase in tonsillar cancer of 2 to 3% may be similar with the base of tongue category, 
but not as much focus has been placed on this location.  Due to the significant findings of this 
small case-control study and the possible role these findings would play in prevention, 
clinical treatment and improved outcomes for cancer patients, there is a need to expand the 
study and utilize a larger sample size of this same population. This will enable confirmation 
of the preliminary findings as well as to identify and define other independent variables and 
biomarkers which have a role in the etiology and pathogenesis of HPV associated oral 
cancers. Information from future studies will help in the identification of those who should 
have further testing. An expanded study will also be a bridge to a larger, possible multi-
center study in which the analysis would expand to include patients with a history of 
smoking and/or drinking and their intimate partners.  
Formulation of a screening protocol is also needed to help identify those at risk. An 
eventual study of screening protocols, as well as testing of a decision tree and the treatments 
which will be defined by the biomarkers previously identified would be a future goal. If a 
patient is identified earlier the long term morbidity and mortality which is associated with 
this type of disease can be reduced. Also we may see a reduction in this subset of cancers. 
Patients with HPV related cancers can be treated differently than the traditional oral cancer 
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patient as these cancers respond more effectively to chemo-radiation and these patients also 
have a better long term prognosis. 
Development of a protocol to identify persons at risk for this infectious type of cancer 
is crucial. (See Figure 4.1 Proposed Oropharyngeal Screening Protocol) Early identification 
of the virus in other similar intimate partners may provide a definitive method to reduce the 
incidence of these malignancies (10). Most oral and oropharyngeal cancers go unidentified 
until it is too late for conservative intervention. If a screening method is designed that can be 
easily used by healthcare professionals, both dentists and MD’s, to identify those at risk for 
developing these lesions, we may be able to eliminate 20% of HNSCC.  
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Figure 4.1  Proposed Oropharyngeal Screening Protocol. This is an example of how 
a healthcare provider may approach the decisions on HPV screening. This screening 
would  be performed at the patients annual physical or at their dental exam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We know that virtually all cervical cancers are caused by sexually transmitted HPV 
infection (9). Typically the majority of these cancers are HPV16 +.  We also know that HPV-
16 alone accounts for more than 90% of cases of HPV-positive squamous-cell carcinomas of 
the head and neck (11).  A more accurate and probably higher proportion might be found by 
testing for other types of HPV (e.g., types 18, 31, 33, and 35), which are infrequently 
detected in oropharyngeal cancers. This is supported by our findings of HPV 18 in tonsils, as 
well as base of tongue and oral tongue biopsies. 
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We have identified a tight link between HPV and squamous cell carcinomas, early 
identification of the virus may provide a crucial marker of high-risk susceptibility for 
developing these malignancies (12). The public health implications of our findings are 
underscored by the annual increases in the incidence of tonsillar and base-of-tongue cancers 
in the United States since 1973. The widespread oral sexual practices among adolescents may 
be a contributing factor in this increase (13).  Early identification of the virus in other similar 
intimate partners may provide a definitive method to reduce the incidence of these 
malignancies (10). Development of a protocol to identify persons at risk for this infectious 
type of cancer is crucial.  
Approximately 20% of adults become infected with HPV16 in their lifetime. 
Prophylactic HPV vaccines based on virus-like particles (VLPs) have been successfully 
tested in clinical trials. These vaccines are safe and effective in the prevention of persistent 
infection and subsequent pre-malignant cervical disease, and are now being introduced onto 
the market (4). The presence of HPV in orophayngeal cancers may warrant the use of 
vaccination in boys as well as girls 9-15 years of age, for oral cancer prophylaxis.  As HPV is 
suspected in 1/5 of head and neck cancers, prophylaxis may result in a significant decrease in 
the incidence of disease.  The revelations afforded by this study have significant public 
health implication and will be pivotal to the management and counseling of HPV infected 
cancer patients.   
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